Anavex Life Sciences Corp. (NASDAQ:AVXL) was up NaN on Friday . The company traded as high as $4.75 and last traded at $0.00. Approximately 1,079,700 shares were traded during mid-day trading, an increase of Infinity from the average daily volume of 0 shares.

AVXL has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a report on Monday, September 18th. ValuEngine downgraded Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a report on Friday, June 30th. Finally, Maxim Group restated a “buy” rating and set a $15.00 price target on shares of Anavex Life Sciences Corp. in a report on Thursday, July 20th.

The firm’s market cap is $180.50 million. The stock’s 50-day moving average price is $4.27 and its 200 day moving average price is $4.27.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). Analysts forecast that Anavex Life Sciences Corp. will post ($0.37) earnings per share for the current year.

Several institutional investors have recently bought and sold shares of the company. American International Group Inc. raised its stake in shares of Anavex Life Sciences Corp. by 7.1% during the first quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 1,329 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Anavex Life Sciences Corp. by 5.7% during the second quarter. Teachers Advisors LLC now owns 67,746 shares of the biotechnology company’s stock valued at $360,000 after acquiring an additional 3,681 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Anavex Life Sciences Corp. by 12.1% during the second quarter. Wells Fargo & Company MN now owns 40,385 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 4,347 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Anavex Life Sciences Corp. by 12.9% during the first quarter. Bank of America Corp DE now owns 39,981 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 4,561 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Anavex Life Sciences Corp. by 14.8% during the second quarter. Rhumbline Advisers now owns 40,342 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 5,205 shares in the last quarter. 24.41% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/10/13/anavex-life-sciences-corp-avxl-trading-up-nan.html.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.